|
1) Nakagawa Y, Iwasaki Y, Kimura T, et al. Serial angiographic follow-up after successful direct angioplasty for acute myocardial infarction. Am J Cardiol. 1996; 78: 980-4
|
|
|
|
2) Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med. 1999; 341: 1949-56
|
|
|
|
|
|
3) Zhu MM, Feit A, Chadow H, et al. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol. 2001; 88: 297-301
|
|
|
|
|
|
4) Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349: 1315-23
|
|
|
|
|
|
5) Guidelines for the management of patients with ST-elevation myocardial infarction (JCS 2008) Circ J. 2008; 72 Suppl; 1347-411
|
|
|
|
|
6) Saia F, Lemos PA, Lee CH, et al. Sirolimus-eluting stent implantation in ST-elevation acute myo-cardial infarction: a clinical and angiographic study. Circulation. 2003; 108: 1927-9
|
|
|
|
|
|
7) Lemos PA, Saia F, Hofma SH, et al. Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol. 2004; 43: 704-8
|
|
|
|
|
|
8) Hannan EL, Racz M, Walford G, et al. Drug-eluting versus bare-metal stents in the treatment of patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2008; 1: 129-35
|
|
|
|
|
|
9) Pierre-Louis B, Aronow WS, Palaniswamy C, et al. Major adverse cardiac events at follow-up after bare-metal stenting versus drug-eluting stenting in ST-elevated myocardial infarction. Am J Cardiol. 2009; 103: 1672-4
|
|
|
|
|
|
10) Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myo-cardial infarction. N Engl J Med. 2006; 55: 1093-104
|
|
|
|
|
|
11) Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med. 2009; 360: 1946-59
|
|
|
|
|
|
12) Kimura T, Morimoto T, Nakagawa Y, et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation. 2009; 119: 987-95
|
|
|
|
|
|
13) Nakagawa Y. DES vs. BMS in patients with ST-elevation myocardial infarction, from j-Cypher registry (Should drug eluting stents be indicated for the patients with acute coronary syndrome？). Circ J. 2009; 78 Suppl; 78[abstract]
|
|
|
|
|
|
14) Kimura T, Morimoto T, Furukawa Y, et al. Long-term safety and efficacy of sirolimus-eluting stents versus bare-metal stents in real world clinical practice in Japan. Cardiovasc Interv and Ther. 2011; 26: 234-45
|
|
|
|
|
|
15) Nakazawa G, Finn AV, Joner M, et al. Delayed arterial healing and increased late stent throm-bosis at culprit sites after drug-eluting stent place-ment for acute myocardial infarction patients: an autopsy study. Circulation. 2008; 118: 1138-45
|
|
|
|
|
|
16) Nakagawa Y. What is the effectiveness of drug-eluting stents in the treatment of ST-elevation myocardial infarction？ Circ J. 2010; 74: 2225-31
|
|
|
|